Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety & Risk Management Advisory Committee, and the Pediatric Advisory Committee

December 10, 2008

 

 

SLIDES

 

 

FDA

Opening Remarks, Badrul A. Chowdhury, MD, PhD, Director, Division of Pulmonary and Allergy Products, OND/CDER (pdf) (html) 

 

Sally Seymour, MD, Deputy Director for Safety,Division of Pulmonary and Allergy Products, OND/CDER (pdf) (html)

 

Andrew D. Mosholder, M.D., M.P.H., Medical Officer, Division of Epidemiology

Office of Surveillance and Epidemiology/CDER (pdf) (html)

 

Mark Levenson, Ph.D., Statistical Safety Reviewer, Quantitative Safety and Pharmacoepidemiology Group, DB6/OB/OTS/CDER (pdf) (html)

 

Ann W. McMahon, MD, MS, Acting Director, Division of Pharmacovigilance II,

Office of Surveillance and Epidemiology/CDER (pdf) (html)

 

David J. Graham, MD, MPH, Associate Director for Science and Medicine

Office of Surveillance and Epidemiology/CDER (pdf) (html)

 

Badrul A. Chowdhury, MD, PhD, Director, Division of Pulmonary and Allergy Products, OND/CDER (pdf) (html)

   

Guest Speaker

Robert F. Lemanske, Jr., M.D., Professor of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health Madison, WI (pdf) (html)

   

Sponsors

GlaxoSmithKline (pdf)

 

Novartis Pharmaceuticals Corporation (pdf)

 

AstraZeneca (pdf)

---

Up | AC Home Page